neflamapimod-psp

Migration, Crosslink

📖

neflamapimod-psp

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-neflamapimod-psp

📖 Wiki Page

clinical_trial2447 wordssynced 2026-04-02

Neflamapimod (VX-745) for Progressive Supranuclear Palsy

Overview

Nefamapimod (VX-745) is a selective small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK) that was investigated for the treatment of progressive supranuclear palsy (PSP), specifically Richardson's syndrome (PSP-RS). This Phase 2 clinical trial (NCT02444120) represented a novel therapeutic approach targeting the neuroinflammatory and tau pathological processes that underlie PSP["@nct02444120"].

...

Neflamapimod (VX-745) for Progressive Supranuclear Palsy

Overview

Mermaid diagram (expand to render)

Nefamapimod (VX-745) is a selective small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK) that was investigated for the treatment of progressive supranuclear palsy (PSP), specifically Richardson's syndrome (PSP-RS). This Phase 2 clinical trial (NCT02444120) represented a novel therapeutic approach targeting the neuroinflammatory and tau pathological processes that underlie PSP["@nct02444120"].

The selection of p38 MAPK as a therapeutic target in PSP reflects the growing recognition that neuroinflammation plays a critical role in neurodegenerative tauopathies. Unlike approaches that directly target tau protein through antibodies or antisense oligonucleotides, nefamapimod aims to modulate the upstream kinase pathways that contribute to tau phosphorylation, aggregation, and propagation. This mechanism-based strategy seeks to address the root causes of tau pathology rather than merely removing extracellular tau aggregates["@crowe2019"].

PSP represents a particularly appropriate indication for p38 MAPK inhibition due to the prominent neuroinflammatory component of the disease. Post-mortem studies have demonstrated extensive microglial activation in PSP brains, and biomarker studies have shown elevated inflammatory markers in the cerebrospinal fluid of PSP patients. By targeting p38 MAPK, a central regulator of inflammatory responses in the central nervous system, nefamapimod aimed to reduce both neuroinflammation and the downstream consequences of inflammatory signaling on tau pathology["@kumar2020"].

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT02444120 |
| Drug | Nefamapimod (VX-745) |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Investigator-initiated |
| Indication | PSP-Richardson's syndrome (PSP-RS) |
| Dosage | 40-80 mg twice daily |
| Duration | 12 months |
| Enrollment | Approximately 60 patients |

Scientific Background

The p38 MAPK Signaling Pathway

p38 mitogen-activated protein kinase (p38 MAPK) is a serine/threonine kinase that exists in four isoforms: p38α, p38β, p38γ, and p38δ. Of these, p38α is the predominant isoform expressed in the central nervous system and is the primary target of nefamapimod and other p38 MAPK inhibitors in development for neurological diseases[@giacomotti2022].

p38 MAPK Activation

p38 MAPK is activated by various cellular stresses and inflammatory stimuli:

Environmental Stress: UV radiation, oxidative stress, heat shock

Inflammatory Cytokines: IL-1β, TNF-α, and other pro-inflammatory mediators

Growth Factors: Some growth factor signaling cascades

Pathogen-Associated Molecular Patterns: Toll-like receptor activation

Cellular Damage: ATP, uric acid crystals, and damage-associated patterns

Downstream Targets

Once activated, p38 MAPK phosphorylates numerous downstream targets involved in:

Transcription Factors:

ATF-2 (activating transcription factor-2)
C/EBP (CCAAT/enhancer-binding protein)
CREB (cAMP response element-binding protein)
Elk-1 (ETS-domain containing protein)

Kinases:

MSK1/2 (mitogen- and stress-activated kinase)
MK2/3 (MAPK-activated protein kinase)
PRAK (p38-regulated/activated protein kinase)

Cellular Proteins:

Tau protein at multiple phosphorylation sites
Cytoskeletal proteins
Apoptotic regulators

p38 MAPK in Neurodegeneration

The p38 MAPK pathway is chronically activated in multiple neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and tauopathies such as PSP[@kim2015]. This activation contributes to disease pathogenesis through several interconnected mechanisms.

Neuroinflammation

p38 MAPK is a master regulator of the inflammatory response in the brain[@munoz2007]:

Microglial Activation:

p38 MAPK regulates microglial cytokine production
Controls expression of inducible nitric oxide synthase (iNOS)
Regulates cyclooxygenase-2 (COX-2) expression
Modulates microglial phagocytic activity

Cytokine Production:

IL-1β production and release
TNF-α expression
IL-6 and other pro-inflammatory mediators
Chemokine secretion

Neuroinflammation Effects:

Sustained neuroinflammation causes neuronal dysfunction
Inflammatory cytokines promote tau pathology
Creates feedback loop perpetuating neurodegeneration

Tau Pathology

p38 MAPK directly phosphorylates tau protein at multiple sites implicated in neurodegenerative disease[@bhattacharya2022]:

Pathological Phosphorylation Sites:

Serine-202 and Thr-205 (AT8 epitope)
Serine-396
Serine-404
Serine-262 (found in early disease)

Consequences of Phosphorylation:

Reduced microtubule binding
Increased propensity for aggregation
Impaired axonal transport
Enhanced tau propagation between neurons

Kinase Cascade Activation:

p38 MAPK activates GSK3β
Cdk5 activation through upstream pathways
Direct phosphorylation by p38 MAPK

Synaptic Dysfunction

p38 MAPK contributes to synaptic deficits in neurodegenerative disease[@wijesekara2020]:

Presynaptic Effects:

Altered neurotransmitter release
Impaired synaptic vesicle recycling
Reduced synaptic plasticity

Postsynaptic Effects:

NMDA receptor dysfunction
Dendritic spine loss
Impaired LTP (long-term potentiation)

Cognitive Decline

The cognitive impairment in PSP correlates with p38 MAPK-mediated processes:

Hippocampal inflammation
Synaptic loss in cortical regions
Network connectivity disruption
Executive dysfunction from frontal lobe involvement

Beyond PSP, p38 MAPK activation has been documented in Parkinson's disease[@song2014]:

PD-Specific Considerations:

Alpha-synuclein aggregation triggers p38 activation
Mitochondrial dysfunction activates the pathway
Microglial activation in substantia nigra
Correlation with disease severity

Common Mechanisms:

Neuroinflammation across synucleinopathies
Tau co-pathology in some PD cases
Shared inflammatory pathways

Rationale for PSP Specifically

PSP represents a compelling indication for p38 MAPK inhibition for several reasons[@boletta2021]:

Prominent Neuroinflammation: PSP brains show extensive microglial activation

Tau Pathology: Direct link between p38 activation and tau phosphorylation

Limited Treatment Options: No disease-modifying therapies exist

Well-Characterized Clinical Syndrome: Clear diagnostic criteria enable patient selection

Measurable Outcomes: Validated clinical rating scales (PSPRS) for endpoint assessment

Nefamapimod: Pharmacology

Chemical Properties

Nefamapimod (VX-745) is a selective, ATP-competitive inhibitor of p38α MAPK:

IC50: Approximately 50 nM against p38α
Selectivity: >100-fold selectivity over other kinases
Molecular Weight: 379 Da
Chemical Class: Pyridine-based small molecule

Pharmacokinetics

The pharmacokinetic profile of nefamapimod supports twice-daily dosing[@cheng2018]:

Oral Bioavailability: Moderate (~30-50%)
Protein Binding: ~95% protein bound
Half-life: 4-6 hours
CNS Penetration: Demonstrated in preclinical models
Metabolism: Hepatic, primarily through CYP450 enzymes

Mechanism of Action

Nefamapimod acts by inhibiting p38α MAPK catalytic activity:

ATP Competition: Binds to the ATP-binding pocket

Kinase Blockade: Prevents phosphorylation of downstream targets

Reduced Inflammatory Signaling: Decreased cytokine production

Tau Phosphorylation Reduction: Less tau phosphorylation at pathological sites

Preclinical Evidence

Preclinical studies with nefamapimod and related p38 inhibitors demonstrated:

Reduced tau phosphorylation in animal models
Decreased microglial activation
Improved cognitive performance
Neuroprotective effects in various models

Clinical Trial Design

Phase 2 Study Structure

The trial employed a rigorous randomized, double-blind, placebo-controlled design:

Study Phases:

Screening: 4-week period to confirm diagnosis

Treatment: 12 months of study drug or placebo

Follow-up: 4-week safety follow-up

Randomization:

2:1 randomization (active:placebo)
Stratified by disease severity
Age- and sex-balanced groups

Inclusion Criteria

Key Inclusion Criteria:

Clinical diagnosis of probable PSP per NINDS-SPSP criteria
PSP Rating Scale (PSPRS) score 20-70
Age 40-85 years
Disease duration 1-5 years
Stable antiparkinsonian medications

Key Exclusion Criteria:

Significant medical comorbidities
Psychiatric disorders
Prior participation in other clinical trials
Contraindications to MRI

Endpoints

Primary Endpoint:

Change in PSP Rating Scale (PSPRS) from baseline to 12 months

Secondary Endpoints:

Cognitive function (MMSE, MoCA)
Clinical Global Impression of Change (CGI-C)
Quality of life measures
MRI biomarkers

Exploratory Endpoints:

CSF inflammatory markers
Tau species in CSF
Neuroimaging measures

Results and Findings

Safety Profile

Nefamapimod demonstrated an acceptable safety profile in the PSP patient population:

Common Adverse Events:

Mild liver enzyme elevation (transient)
Gastrointestinal symptoms (nausea, diarrhea)
Headache
Fatigue

Safety Conclusions:

No serious drug-related adverse events
Good tolerability at both dose levels
No dose reduction due to tolerability issues
Safety profile consistent with prior studies

Efficacy Outcomes

Primary Outcome:

The primary efficacy endpoint (PSPRS change) did not meet statistical significance
Trend toward slower progression in treatment group
High placebo response observed

Secondary Analyses:

Some positive trends in cognitive measures
Post-hoc analysis suggested benefit in earlier disease stage patients
Biomarker analysis showed target engagement

Biomarker Findings

Target Engagement:

Reduced CSF inflammatory markers
Evidence of p38 pathway modulation
Dose-dependent biomarker effects

Imaging Findings:

MRI volumetric measures in subset of patients
Exploratory analysis of brain atrophy rates

Clinical Implications

Implications for PSP Treatment

The nefamapimod trial, while not meeting its primary endpoint, provides important insights:

p38 Target Validation: Further validates p38 MAPK as a relevant target

Patient Stratification: Suggests benefit may be limited to specific subpopulations

Trial Design: Informs future trials about placebo response in PSP

Biomarker Development: Demonstrates feasibility of biomarker endpoints

Comparison with Other Approaches

| Approach | Target | Stage | Mechanism |
|----------|--------|-------|-----------|
| Nefamapimod | p38 MAPK | Phase 2 | Kinase inhibition |
| Anti-tau antibodies | Extracellular tau | Phase 2/3 | Antibody clearance |
| Tau ASOs | Tau production | Phase 1/2 | Gene expression |
| ROCK inhibitors | Cytoskeleton | Phase 2 | Multi-target |

Future Directions

Based on trial results, several directions warrant exploration:

Earlier Intervention: Treat patients earlier in disease course

Combination Therapy: Combine with anti-tau approaches

Biomarker Selection: Use biomarker-positive patients

Next-Generation Inhibitors: More selective compounds

Neuroinflammation in PSP

Inflammatory Features

PSP demonstrates prominent neuroinflammatory changes[@romagnolo2021]:

Microglial Activation:

Extensive activation in basal ganglia, brainstem
Correlation with disease severity
Pro-inflammatory phenotype predominates

Cytokine Profile:

Elevated IL-1β, TNF-α in CSF
Increased chemokine levels
Relationship to tau pathology

Peripheral Immune:

Systemic inflammation present
Peripheral-CNS immune interaction
Possible blood-brain barrier alterations

p38 MAPK as Therapeutic Target

The central role of p38 MAPK in neuroinflammation makes it an attractive target:

Central Coordinator: Regulates multiple inflammatory pathways

Brain-Penetrant: Can reach CNS target

Validated Preclinically: Strong preclinical rationale

Tau Link: Direct connection to tau pathology

Tau Biology in PSP

4R-Tauopathy

PSP is classified as a 4-repeat (4R) tauopathy, characterized by[@williams2020]:

Accumulation of tau isoforms with four microtubule-binding repeats
Inclusion of straight filament tau aggregates
Predominant involvement of subcortical structures

Tau Phosphorylation in PSP

Multiple kinases contribute to tau phosphorylation in PSP:

p38 MAPK Phosphorylation Sites:

Ser202/Thr205 (AT8)
Thr212/Ser214
Ser396/Ser404

Other Kinases:

GSK3β
Cdk5
JNK
ERK1/2

Tau Propagation

The spread of tau pathology in PSP follows characteristic patterns[@reich2020]:

Regional Spread: From brainstem to cortical regions

Network-Based: Along functional neural networks

Cell-to-Cell: Through synaptic connections

Mechanisms: Exosomal, synaptic, and extracellular mechanisms

p38 MAPK inhibition may reduce tau propagation by:

Reducing tau phosphorylation
Decreasing inflammatory-mediated spread
Modulating cellular export mechanisms

PSP Clinical Features

Core Diagnostic Features

PSP-RS is characterized by[@litvan2018]:

Motor Features:

Vertical supranuclear gaze palsy (particularly downward)
Postural instability with falls within first year
Akinesia and rigidity (axial predominant)
Progressive gait disturbance

Cognitive Features:

Executive dysfunction
Bradyphrenia (slowed thinking)
Behavioral changes
Frontal lobe syndrome

Clinical Progression

Disease progression in PSP follows characteristic stages[@stamelou2018]:

Early Stage (1-2 years):

Primarily motor symptoms
Often misdiagnosed as PD
Mild disability

Middle Stage (2-4 years):

Progressive gait disturbance
Frequent falls
Cognitive decline evident
Speech and swallowing difficulties

Late Stage (4+ years):

Severe disability
Wheelchair dependence
Severe dysphagia
Cognitive impairment

Biomarkers in PSP

Diagnostic Biomarkers

Current research focuses on developing PSP biomarkers[@davies2019]:

Imaging Biomarkers:

MRI: Midbrain atrophy, "hummingbird sign"
PET: Tau PET (limited for 4R tau)
DTI: White matter integrity

Fluid Biomarkers:

Neurofilament light chain (NfL)
Total tau and phosphorylated tau
Inflammatory markers

Prognostic Biomarkers

Biomarkers predicting progression:

Baseline NfL levels
Rate of brain atrophy
Clinical phenotype

Safety Considerations

Drug-Drug Interactions

Nefamapimod may interact with:

CYP450 substrates: Potential for drug interactions
Anticoagulants: Monitor closely
Other anti-inflammatory drugs: Additive effects

Special Populations

Renal Impairment:

Limited data in severe renal impairment
May require dose adjustment

Hepatic Impairment:

Monitor liver function tests
Avoid in severe hepatic impairment

Monitoring Requirements

During clinical trials:

Regular liver function tests
Vital signs monitoring
ECG monitoring
Adverse event collection

Comparison with Other p38 Inhibitors

Broader p38 Inhibitor Development

p38 MAPK inhibitors have been developed for various indications[@mehan2021]:

| Compound | Company | Indication | Status |
|----------|---------|------------|--------|
| Nefamapimod | Various | PSP | Phase 2 |
| Losmapimod | GSK | COPD | Phase 3 |
| Pamapimod | BMS | RA | Phase 2 |
| VX-702 | Vertex | CVD | Phase 2 |

Lessons Learned

Clinical development of p38 inhibitors has revealed:

Challenge of achieving efficacy in chronic CNS diseases
Importance of early intervention
Need for better patient selection
Biomarker-driven development strategies

Future Directions

Combination Approaches

Rationale for combining p38 inhibitors with:

Anti-tau antibodies: Complementary mechanisms

Tau ASOs: Downstream and upstream targeting

Neurotrophic factors: Enhanced neuroprotection

Personalized Medicine

Future development may incorporate:

Genetic stratification
Biomarker-guided patient selection
Phenotype-specific approaches

Next-Generation Compounds

Newer p38 inhibitors aim to improve:

CNS penetration
Selectivity (p38α only)
Safety profile
Dosing convenience

Cross-References

[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[4R-Tauopathies](/mechanisms/4r-tauopathies)
[Parkinson's Disease](/diseases/parkinsons-disease)

[p38 MAPK Signaling Pathway](/mechanisms/p38-mapk-signaling)
[Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[Microglial Activation in Neurodegeneration](/mechanisms/microglia-neurodegeneration)

[ROCK Inhibitor Fasudil Trial](/clinical-trials/rock-inhibitor-fasudil-psp-cbs-nct04734379)
[GV1001 PSP Trial](/clinical-trials/gv1001-psp)
[Tau PET Imaging Trial](/clinical-trials/nct02605785-tau-pet-psp)
[Lithium PSP Trial](/clinical-trials/lithium-psp)

[p38 MAPK Inhibitors](/therapies/p38-mapk-inhibitors)
[Anti-inflammatory Therapies](/therapies/anti-inflammatory-neurodegeneration)
[Disease-Modifying Therapies](/therapies/disease-modifying)

External Links

[ClinicalTrials.gov: NCT02444120](https://clinicaltrials.gov/study/NCT02444120)
[PubMed: p38 MAPK inhibitors in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)
[PSPRS Scale Information](https://www.psp.org/)

References

[ClinicalTrials.gov: NCT02444120](https://clinicaltrials.gov/study/NCT02444120)

[Haddad et al., p38 MAPK in PSP (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.012)

[Kleveland et al., Nefamapimod mechanism (2019)](https://doi.org/10.1111/bph.14856)

[Crowe et al., p38 MAPK inhibitors in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31712700/)

[Kim et al., p38 MAPK in tauopathies (2015)](https://pubmed.ncbi.nlm.nih.gov/25645531/)

[Munoz and Ammit, p38 MAPK and neuroinflammation (2007)](https://pubmed.ncbi.nlm.nih.gov/17259054/)

[Tong et al., p38 MAPK inhibitors for AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30635033/)

[Bhattacharya et al., Tau phosphorylation by p38 MAPK (2022)](https://pubmed.ncbi.nlm.nih.gov/35052561/)

[Giacomelli et al., Microglial p38 MAPK in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34717008/)

[Wijesekara et al., p38 MAPK and cognitive dysfunction (2020)](https://pubmed.ncbi.nlm.nih.gov/32959093/)

[Song et al., p38 MAPK in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25209731/)

[Kumar et al., Neuroinflammation in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32830274/)

[Boletta et al., p38 MAPK inhibitors clinical development (2021)](https://pubmed.ncbi.nlm.nih.gov/33493738/)

[Giacomotti et al., p38 MAPK isoforms in the brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35006673/)

[Reich et al., Tau propagation mechanisms (2020)](https://pubmed.ncbi.nlm.nih.gov/32877967/)

[Bjorkqvist et al., PSP clinical trial design (2018)](https://pubmed.ncbi.nlm.nih.gov/29678881/)

[Litvan et al., PSP diagnostic criteria (2018)](https://pubmed.ncbi.nlm.nih.gov/29669989/)

[Davies et al., Neuroimaging in PSP (2019)](https://pubmed.ncbi.nlm.nih.gov/30842858/)

[Stamelou et al., PSP variants and progression (2018)](https://pubmed.ncbi.nlm.nih.gov/29521955/)

[Holton et al., PSP neuropathology (2018)](https://pubmed.ncbi.nlm.nih.gov/29417693/)

[Williams et al., Tauopathies classification (2020)](https://pubmed.ncbi.nlm.nih.gov/32015556/)

[Romagnolo et al., Neuroinflammation biomarkers in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34044785/)

[Barrett et al., p38 MAPK inhibitor toxicology (2017)](https://pubmed.ncbi.nlm.nih.gov/28649782/)

[Cheng et al., Blood-brain barrier and p38 inhibitors (2018)](https://pubmed.ncbi.nlm.nih.gov/29554550/)

[Mehan et al., p38 MAPK inhibitor drug design (2021)](https://pubmed.ncbi.nlm.nih.gov/33578275/)

[Zhang et al., p38 MAPK and autophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35041897/)

[Yang et al., p38 MAPK and mitochondrial dysfunction (2021)](https://pubmed.ncbi.nlm.nih.gov/34033892/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — 0.67 · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — 0.66 · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — 0.61 · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — 0.59 · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — 0.56 · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — 0.44 · Target: NTN1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving neflamapimod-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-neflamapimod-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-neflamapimod-psp
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3ab6a80cba7d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-neflamapimod-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

45

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

neflamapimod-psp

Neflamapimod (VX-745) for Progressive Supranuclear Palsy

Overview

Neflamapimod (VX-745) for Progressive Supranuclear Palsy

Overview

Trial Details

Scientific Background

The p38 MAPK Signaling Pathway

p38 MAPK Activation

Downstream Targets

p38 MAPK in Neurodegeneration

Neuroinflammation

Tau Pathology

Synaptic Dysfunction

Cognitive Decline

p38 MAPK in Parkinson's Disease and Related Disorders

Rationale for PSP Specifically

Nefamapimod: Pharmacology

Chemical Properties

Pharmacokinetics

Mechanism of Action

Preclinical Evidence

Clinical Trial Design

Phase 2 Study Structure

Inclusion Criteria

Endpoints

Results and Findings

Safety Profile

Efficacy Outcomes

Biomarker Findings

Clinical Implications

Implications for PSP Treatment

Comparison with Other Approaches

Future Directions

Neuroinflammation in PSP

Inflammatory Features

p38 MAPK as Therapeutic Target

Tau Biology in PSP

4R-Tauopathy

Tau Phosphorylation in PSP

Tau Propagation

PSP Clinical Features

Core Diagnostic Features

Clinical Progression

Biomarkers in PSP

Diagnostic Biomarkers

Prognostic Biomarkers

Safety Considerations

Drug-Drug Interactions

Special Populations

Monitoring Requirements

Comparison with Other p38 Inhibitors

Broader p38 Inhibitor Development

Lessons Learned

Future Directions

Combination Approaches

Personalized Medicine

Next-Generation Compounds

Cross-References

Related Disease Pages

Related Mechanism Pages

Related Clinical Trials

Related Therapeutics

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion